Stockreport

Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec

CYTODYN INC  (CYDY) 
NASDAQ:AMEX Investor Relations: ir.cytodyn.com
PDF The 60 double-blinded arm (700 mg) will be unblinded by early December VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a l [Read more]